Lemtrada Stroke and Arterial Tears Risk



The U.S. Food and Drug Administration (FDA) has put forth an urgent safety alert, in regards to some rare but very life-threatening risks including stroke and artery rupture. The patients at risk are those who have relapsing forms of multiple sclerosis (MS) and are currently being treated with Lemtrada (alemtuzumab). Since Lemtrada’s approval in 2014 to treat relapsing MS, 13 cases worldwide have been…

https://www.napolilaw.com/article/lemtrada-stroke-and-arterial-tears-risk/

Comments

Popular posts from this blog

Having a Safe and Fun Time at a Campground

#MeToo Takes Center Stage At New York Fashion Week

Nursing Home Elder Abuse During the COVID-19 Outbreak